Legislation passed the House of Representatives on June 25 that would appropriate $100,000 for the U.S. Food and Drug Administration (FDA) to perform a Health Hazard Evaluation (HHE) and set a safe level of CBD for consumers to use each day. The process would follow the same precedent as red yeast rice, which allows a natural product to contain a level of a drug ingredient that the FDA has determined to be safe.
“This is a promising new product that Americans are excited about, but science and public health concerns must always come first,” said Daniel Fabricant, PhD, president and CEO of the Natural Products Association (NPA). “NPA is leading this effort because we believe strongly in a clear and fair regulatory approach for all new ingredients.”
- On May 31, 2019, NPA testified at the FDA’s first public hearing on CBD.
- On March 14, 2019, NPA submitted official comments to the FDA concerning approaches to CBD regulation that will also help facilitate the discussion.
- On October 24, 2018, NPA sent a letter to FDA asking for regulatory leadership on CBD products.
For more information, visit www.npanational.org.
